Sarah Warren

TL;DR: B cell markers were the most differentially expressed genes in the tumours of responders versus non-responders and insights are provided into the potential role of B cells and tertiary lymphoid structures in the response to ICB treatment, with implications for the development of biomarkers and therapeutic targets.

TL;DR: It is found that the co-occurrence of tumour-associated CD8 + T cells and CD20 + B cells, and the formation of tertiary lymphoid structures, are linked with improved survival in cohorts of patients with metastatic melanoma.

TL;DR: An updated operational definition of immunogenic cell death is provided, the key factors that dictate the ability of dying cells to drive an adaptive immune response are discussed, and experimental assays that are currently available for the assessment of ICD in vitro and in vivo are summarized.

TL;DR: It is found that activating the non‐canonical NF‐&kgr;B transcription factor pathway amplified IL‐12‐producing DCs and sensitized tumors to anti‐PD‐1 treatment, suggesting a therapeutic strategy to improve responses to checkpoint blockade.

TL;DR: It is found that neoadjuvant ipilimumab + nivolumab expand more tumor-resident T cell clones than adjuvant application, and warrants future evaluation with modified dosing schedules to reduce treatment-related adverse events.